Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort.
Robin Kate Kelley
Research Funding - Regeneron
Lillian L. Siu
Research Funding - Regeneron
Katherine Van Loon
No relevant relationships to disclose
Anthony W. Tolcher
Consultant or Advisory Role - Regeneron (U); Sanofi
Albiruni R. A. Razak
No relevant relationships to disclose
Sharvina Ziyeh
No relevant relationships to disclose
Muralidhar Beeram
Research Funding - Regeneron
Philippe L. Bedard
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi
Rebecca Arcos
No relevant relationships to disclose
Bo Gao
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Pamela Trail
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Lieve Adriaens
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Carrie M. Brownstein
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Israel Lowy
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Kyriakos P. Papadopoulos
Research Funding - Regeneron